HIV infection, AIDS, and antiretroviral therapy (ART) have been associated with bone fragility fractures, although the prevalence and incidence are not well studied by researchers. In HIV and ART, osteopenia and osteoporosis are multifactorial, and health promotion or medical health maintenance should anticipate and prevent morbidity of bone fragility fractures.
Introduction
Several studies have reported a high prevalence of decreased bone mineral density (BMD) in HIV-infected patients on ART with a range from 22 percent to 50 percent for osteopenia, and 3 percent to 21 percent for osteoporosis. [1] [2] [3] [4] The direct relationship between ART and decreased BMD remains in question. Indeed, several studies have implied that HIV itself may be responsible over time for at least some of these effects on bone. [5] [6] [7] [8] [9] HIV could affect bone density directly or indirectly by systemic activation of T cells. Although the pathogenesis of the bone abnormalities remains unclear, it is potentially multifactorial, possibly involving HIV, ART, and other non-treatment factors. Non-treatment factors include smoking, heavy alcohol intake, severe weight loss, hyperthyroidism, hypogonadism, disruption of the parathyroid hormone axis, malabsorption, micronutrient deficiency, and other medications, such as corticosteroids, phenobarbital, and anticoagulants. Despite documentation of high prevalence of low BMD in this population, the clinical implications of these findings remain uncertain, and a clear understanding of the natural history of osteopenia in HIV-infected patients, its clinical consequences, and effective management has yet to emerge. In particular, the prevalence and management of fragility fractures are unknown. Since a significant number of HIV-infected patients in Western countries are young, otherwise healthy men with good virologic control and non-sedentary life styles, it is tempting to speculate that they may not be as predisposed to fractures as other populations with equivalent rates of BMD loss, such as post-menopausal women. Indeed, it is remarkable that very few non-traumatic fractures have been reported in HIV-infected patients. [10] [11] [12] [13] Whether this represents a real absence of fractures or simply underreporting requires clarification. This report describes the clinical and laboratory characteristics of fragility fractures among HIV-infected patients, as well as their clinical management.
Study design
Seventeen large HIV clinics were contacted by e-mail and asked to identify cases of fragility fractures in HIVinfected patients from their medical records and by providers' inquiry. Patients with radiological findings consistent with fractures and a clinical history of fractures occurring in the absence of trauma or after trivial trauma were included in the study. Not included were patients with fractures from high-energy traumatic injury (eg, a motor vehicle accident). The characteristics of both HIV infection and bone disease in the study group were investigated and documented from the medical charts. identifiable confidential patient information because patients were assigned numbers. The forms gathered data on five groups of characteristics: 1) demographics and clinical characteristics (eg, age, sex, race, body mass index (BMI), family history of bone disease, smoking and alcohol history, co-morbidities, current medications); 2) characteristics of HIV infection (eg, HIV duration, nadir CD4 count, CD4 count and HIV-1 RNA at the time of fracture, or if unavailable, at the closest available time point to the fracture, ART history, and antimicrobial chemoprophylaxis received); 3) characteristics of the bone fracture events (eg, situation surrounding the fracture, location, the time between HIV diagnosis and the facture); 4) diagnosis of fracture (eg, assessment of bone loss by dual energy X-ray absorptiometry (DEXA) scan testing, bone-related laboratory investigations, including calcium, phosphorus, alkaline phosphatase, thyroid-stimulating hormone (TSH), 25-hydroxy-vitamin D, lactate, parathyroid hormone (PTH), and follicular stimulating hormone (FSH)), and management of fracture, particularly bonerelated therapies, or switches in ART); and 5) outcome data for fracture as evaluated clinically from the time of fracture diagnosis until the last documented clinic visit.
Results
Overall, four sites reported being unaware of any cases of fragility fractures (only one of these sites ran a formal database query); four sites identified between one and five cases each, but subsequently declined to participate; and the participating nine study sites collected a total of 55 patients with fragility fractures. Only three of the nine sites ran formal electronic database queries of ICD-9 codes; the other sites relied on cases recalled by physicians and nurses. All sites conducted the study within the guidelines of the Institutional Review Board (IRB) at their respective site.
Demographics and clinical characteristics: The median date of fracture was July 2001 (range February 1991 to August 2003); only two cases occurred before April 1996. Baseline demographics and characteristics are summarized in Table 1 . Overall, 43/55 (78 percent) were male. Race was documented in 46/55 (82 percent): 32/46 (70 percent) were white, 11/46 (24 percent) black, and 3/46 (6 percent) Hispanic. Median age at the time of fracture was 45 years (range 25 to 75 years).
Smoking status was documented in 48 patients (87 percent); among them, 22 (46 percent) were current smokers at the time of fracture, and 10 others (21 percent) were past users. Forty-six patients (84 percent) had documentation of their alcohol status. Current excessive alcohol use was noted in 7/46 (15 percent) and past excessive use in another 5/46 (11 percent). Documented height and weight at the time of fracture were available from 42 patients. Median BMI calculated in this group (n=42) was 22.69 kg/m 2 (range 15.81 to 32.25 kg/m 2 ). Seven patients had a history of steroid use (chronic use reported in two patients with chronic lung disease and one with adrenal insufficiency). The other four had prior short courses of steroids, mainly for Pneumocystis carinii pneumonia or chronic obstructive pulmonary disease exacerbations.
Characteristics of HIV infection: The median known duration of HIV infection at the time of fracture (n=54) was nine years (range 0.1 to 19 years). Five patients presented with fracture within six months of the first known positive HIV test. The median nadir CD4 count (n=52) was 50 cells/mm 3 (range 0 to 498). At time of fracture, HIV-1 RNA and CD4 count were available from 51 and 52 patients, respectively; median HIV-1 RNA was 473 copies/mL (range <50 to 4,508,000) and 23/51 (45 percent) were <400 copies/mL. At the time of fracture, median CD4 count was 174 cells/mm 3 (range 7 to 908). Antiretroviral history was available for 93 percent (51/55) of study patients, three of whom had never received ART. Among the 48 patients on ART at any time prior to fracture, the median cumulative ART duration at the time of fracture (and of exposure to nucleoside reverse transcriptase inhibitors (NRTIs)) was 39 months (range <1 to 142). The median cumulative duration of protease inhibitor (PI)-containing therapy was 20 months (range 0 to 83) with 27 percent (13/48) of patients having received PIs for less than six months at the time of fracture.
At the time of fracture, 41 patients were receiving ART, with 33 receiving at least one PI. The most commonly used NRTI was lamivudine (3TC) (34 patients), followed by stavudine (d4T) (15 patients); zidovudine (ZDV) (11 patients); abacavir (ABC) (10 patients); tenofovir (TDF) (nine patients); didanosine (ddI) (three patients); emtricitabine (FTC) (one patient); and zalcitabine (ddC) (one patient). Ten patients were receiving a nonnucleoside reverse transcriptase inhibitor (NNRTI): five used efavirenz (EFV); four used nevirapine (NVP); and one used delavirdine (DLV). The most commonly used PI was nelfinavir (NFV) (13 patients), followed by ritonavir (RTV) (12 patients; only one in full dose); indinavir (IDV) (11 patients); lopinavir (LPV) (five patients); saquinavir (SQV) (two patients); and amprenavir (APV) and atazanavir (ATV) (one patient each). Three patients were receiving enfuvirtide (ENF, T-20).
Characteristics of fracture events: Sixty percent (33/55) of the fractures occurred in the absence of any trauma, and 40 percent (22/55) occurred after minor trauma. The majority of minor traumas were described as falls from a standing height. Three of the atraumatic fractures were associated with tumors or metastases.
The most common fracture location was vertebral, either as the sole location (27 patients), or in association with foot (one patient), femur (one patient), or pelvis (one patient). Other locations varied significantly: lower extremities (16 patients)-most commonly femur, ribs (four patients), upper extremities (three patients), and clavicle (two patients).
Diagnostic investigations and management of fractures:
Only 11 out of the 55 patients (20 percent) with fragility fractures underwent DEXA scanning. Patients with a DEXA scan had a more recent median fracture date than those without a DEXA scan (June 2002 versus July 2001, respectively). Evaluation of the lumbar spine BMD led to 36 percent (4/11) of patients being diagnosed with osteoporosis (by World Health Organization (WHO) classification of t-score <-2.5); and another 45 percent (5/11) with osteopenia (t-score between -1 and -2.5). Two patients had lumbar spine t-scores within normal range (0.11 and -0.23). The median lumbar spine t-score was -2.38 (range 0.11 to -5.6). The assessment of hip BMD yielded the following results: 36 percent, 36 percent, and 27 percent had osteoporosis (t-score <-2.5), osteopenia (-2.5<t-score<-1), and normal t-scores, respectively. The median hip t-score was -1.98 (range 0.51 to -3.58).
Overall, appropriate laboratory investigations for fragility fractures were performed on a small number of patients. Levels of 25-hydroxyvitamin D were documented in only 11/55 (20 percent), of whom 3/11 (27 percent) had levels <15 ng/mL. The PTH level was measured in only 10 patients, two of whom had elevated levels >3 X ULN (224 and 361pg/mL, respectively). One of these patients had a low 25 OH-vitamin D level of 9ng/mL; the other had no documentation of vitamin D levels, or of other investigations to elucidate the cause of the hyperparathyroidism. Thyroid function screening with TSH was done in 29/55 (53 percent), and was above the upper limit of normal (ULN) in two patients; one of these had further thyroid investigations that yielded a diagnosis of euthyroidism. The second had neither repeat testing nor further investigations performed, but there were no clinical indications of abnormal thyroid function. Testosterone (total and/or free) levels were measured in 17 males, four of whom were diagnosed with hypogonadism and started on replacement therapy. Only two of the 12 females underwent FSH 
Discussion
Osteopenia and osteoporosis are newly recognized problems in HIV-infected patients. Prevalence rates are higher than reflected in clinical practice or medical health maintenance. Several studies report lower BMD in HIV-infected men and women as compared to age, race, and gender matched controls. 5, 14, 15 More recently, the Women's Interagency HIV Study (WIHS) reported that HIV-infected women had a 6 percent to 8 percent lower BMD (p<-0.03) than HIV-negative controls. 16 HIV infection was an independent risk factor for low bone mass in this study population (odd ratio 3.15; confidence interval, 1.14 to 8.72). 16 The clinical implications of low bone mass in the HIVinfected population are unknown. Intuitively, it would seem likely that patients with decreased BMD are at increased risk for fracture. However, there are no data documenting that low bone mass leads to increased fracture risk in HIV-infected patients. Furthermore, the prevalence of fractures in this population has not been reported. Clinical experience and a few case reports of fractures in HIV-infected men and women prompted our investigation. [10] [11] [12] [13] Our study participants had advanced HIV disease with median nadir CD4 count of only 50 cells/mm 3 , a finding consistent with the reports that HIV is the cause of the bone loss in this population.
Nine HIV clinics identified 55 out of approximately 8,600 patients with fragility fractures through physician recall and/or ICD-9 codes. This may be an underestimate of the real incidence of fragility fractures since many cases were likely missed. In addition, physicians are more likely to recall more recent cases of fractures in their clinics, which could have accounted at least partially to the higher number of cases in the more recent time period. Even though recall bias and limitations of ICD-9 codes may underestimate the prevalence of fragility fracture in our HIV study population, this case series suggests that fragility fractures may be a problem in HIV-infected patients. Consistent with sites of fragility fractures noted in other study populations, such as post-menopausal women, our HIV study population reported the vertebra and hip to be the most common fracture location. Furthermore, BMD was reported to be osteopenic or osteoporotic in 82 percent of patients with DEXA assessments. Traditional risk factors for low bone mass and fractures (eg, advanced age, white race, female gender, menopause), as well as modifiable risk factors (eg, tobacco use, low body weight, androgen/ estrogen deficiency, low calcium intake, alcohol use, steroid use, and low vitamin D25 levels) were documented in our fracture population. Unfortunately, the exact role of these risk factors in the precipitation of fractures in our study population cannot be determined.
The BMD status of HIV-infected patients after ART has received a great deal of attention. A few studies supported higher prevalence and a more severe osteopenia/ osteoporosis in patients on PIs; 2, 17, 18 however, other studies failed to support PI use and bone loss. 1, [19] [20] [21] The variability in ART preparation, dose, and duration, complicated by the HIV disease process, limits our understanding of this issue. Although 87 percent of patients in this study received ART prior to the time of fracture, associations between fracture risk and ART use cannot be determined.
Individuals with fragility fractures in our study population received suboptimal risk factor assessment.
Poor documentation of risk factors, laboratory assessments, and DEXA testing in the medical records of patients corroborates our conclusion. There is no reliable blood marker used routinely to screen for osteopenia or osteoporosis. Tebas et al found that bone alkaline phosphatase inversely correlated with t-scores in the lumbar spine and the hip; 2 however the commonly used non-bone-specific alkaline phosphatase did not correlate, and therefore could not be used as a screening marker. Only 35 percent of patients with fragility fractures reported any therapy to treat their underlying bone disease. Calcium supplementation was the most commonly reported therapy and only 10 percent received appropriate anti-resorptive therapy. Inadequate risk assessment and treatment protocol in this population may have contributed to the 19 percent recurrent fractures noted in our study. Prior studies have demonstrated that a history of fragility fracture between the ages of 20 and 50 years is a significant independent predictor of fractures after the age of 50 years (risk ratio, 1.83; confidence interval, 1.12 to 2.76). 22 Therefore, all patients with fragility fractures should undergo fracture risk assessment and optimal treatment for osteoporosis.
In the HIV-negative population, fragility fractures result in morbidity, mortality, and an increased expenditure of healthcare resources. After a hip fracture, only 50 percent of patients regain their independence after a year; 40 percent are still unable to walk independently; and 60 percent have difficulty with activities of daily living six months later. 23 The direct and indirect costs of caring for these patients are high, resulting in a total cost of US$21,000 per patient for the first year after the fracture. 24 These data are largely derived from elderly females, and may not apply to the HIV-infected population, but they suggest a significant toll in morbidity and mortality for patients with HIV as well.
Since the life span of HIV-infected patients on therapy is increasing, the risk of fracture and subsequent expenditure may also outweigh the cost of osteoporosis treatment. Furthermore, clinically diagnosed vertebral and hip fractures are associated with a respective 19 percent and 18 percent decrease in survival. 25, 26 In the study of osteoporotic fracture, women with one or more vertebral fractures had a 23 percent greater age adjusted mortality compared to women without a fracture. 27 Relative risk of mortality adjusted for age and other risk factors associated with one or more fractures was 1.16. 27 In our HIV-infected fracture population, an allcause mortality rate of 22 percent was reported.
Longitudinal studies of large HIV-infected groups are needed to determine if screening with DEXA scan is appropriate for prediction of future fragility fractures. Such studies will require a long follow-up period since fractures often develop after years of progressive bone loss and incident events appear to be infrequent. Until then, it may be prudent to screen HIV-infected patients at risk for low bone density (eg, hypogonadal men, peri-menopausal/post-menopausal women, individuals on steroid therapy), as well as all individuals with a fracture that occurred after no (or minimal) trauma.
Central DEXA scan to assess spine and hip BMD is the gold standard at the present time. Serum assessment of total calcium, albumin, phosphorus, magnesium, vitamin D 25-OH, Intact PTH, and TSH should also be considered to evaluate potential secondary causes. Regardless of the presence or absence of risk factors, adequate dietary intake of vitamin D and calcium, and appropriate weight-bearing exercise should be recommended to all HIV-infected patients. Similarly, clinicians should encourage HIV-infected patients to curtail smoking and excessive alcohol consumption. In the setting of documented fragility fracture, appropriate therapy with a bisphosphonate should be considered. Studies are ongoing with bisphosphonates to determine their safety and efficacy in HIV-infected patients.
In summary, it is unclear why HIV-infected patients are predisposed to a higher rate of decreased bone density. Associated fractures appear to be underreported, and current management standards are suboptimal. HIVinfected patients may have a significant prevalence of fragility fractures independent of age, gender, and virologic control. The exact rates of atraumatic fractures in the HIV-infected population can only be determined by controlled prospective trials. In other populations, such fractures are associated with significant morbidity, recurrent fractures, and mortality. Therefore, fracture risk assessment and optimal treatment of osteoporosis should be instituted in all HIV-infected patients with fragility fractures. ■
